Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT00636922 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The main goal of this study is to assess the safety and tolerability of RAD001 in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy. The secondary goals are to investigate the likely causes of drug response or failure.

NCT ID: NCT00629798 Completed - Clinical trials for Acute Myeloid Leukemia

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Start date: February 12, 2008
Phase: Phase 2
Study type: Interventional

This study will see if the researchers can lower that risk by giving the patient Palifermin. This drug helps protect the lining of the mouth, throat, and stomach. These areas typically get sores or ulcers while the blood cell counts are very low. The patient can get infections in or from these sores. Palifermin might also help the immune system recover faster. It is currently approved for patients who receive their own stem cells. That is called an autologous transplant. This study will test the use of Palifermin for T-cell depleted allogeneic stem cell transplants.

NCT ID: NCT00620321 Completed - Clinical trials for Acute Myeloid Leukemia

A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to understand the safety profile of LY2181308 sodium administered in combination with idarubicin and cytarabine to patients with relapsed or refractory acute myeloid leukemia (AML).

NCT ID: NCT00615784 Terminated - Clinical trials for Acute Myeloid Leukemia

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

UPCC04407
Start date: May 25, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects within normal and malignant cells that affect cell growth and cell death.

NCT ID: NCT00607997 Completed - Leukemia Clinical Trials

Study of Voreloxin in Older Patients With Untreated Acute Myeloid Leukemia

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the overall remission rate of treatment with voreloxin Injection in patients at least 60 years of age with previously untreated AML

NCT ID: NCT00606216 Completed - Clinical trials for Acute Myeloid Leukemia

Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy

Start date: January 2007
Phase: N/A
Study type: Observational

The purpose of this study is to learn about possible changes in brain anatomy and in thinking abilities, such as memory skills, in patients with cancer who receive treatment with chemotherapy alone or in combination with total body radiation before undergoing stem cell transplantation.

NCT ID: NCT00602225 Completed - Clinical trials for Acute Myeloid Leukemia

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: December 2007
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Colony stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine to see how well it works when given together with cytarabine and G-CSF in treating patients with relapsed or refractory acute myeloid leukemia

NCT ID: NCT00594555 Withdrawn - Clinical trials for Acute Myeloid Leukemia

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of combined chemotherapy treatment (CLAG regimen) with Imatinib Mesylate (Gleevec) in patients with AML.

NCT ID: NCT00593645 Terminated - Clinical trials for Acute Myeloid Leukemia

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Start date: November 2007
Phase: Phase 2
Study type: Interventional

This study will test the combination of clofarabine, cytarabine, and thymoglobulin as a non-myeloablative conditioning regimen for patients with myelodysplastic syndromes or acute myeloid leukemia undergoing allogeneic stem cell transplant.

NCT ID: NCT00593554 Terminated - Clinical trials for Acute Myeloid Leukemia

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Start date: August 7, 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.